Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kalvista Pharmaceuticals Inc (NQ: KALV )

12.09 +0.03 (+0.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kalvista Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents New HAE Attack Journey Data at 2023 US HAEA National Summit
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 US HAEA National Summit
From KalVista Pharmaceuticals
Via Business Wire
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.